Michel 2012.

Methods	Randomised, double‐blinded, placebo‐controlled pilot trial
Participants	12 participants with a supratentorial stroke of unknown onset in the middle cerebral artery territory and significant volume of at‐risk tissue on perfusion computed tomography. 9 of the participants had wake‐up stroke, and 3 had a non‐wake‐up stroke of unknown onset. The study authors contributed unpublished data on the 9 participants with wake‐up stroke.
Interventions	Intravenous tissue plasminogen activator (alteplase) 0.9 mg/kg body weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion Matching placebo
Outcomes	Primary outcome: feasibility of study Secondary outcome: mRS 0 to 2 at 90 days' follow‐up
Notes	Principal Investigator: Patrik Michel, University of Lausanne, Lausanne, Switzerland
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table generated by independent pharmacist
Allocation concealment (selection bias)	Low risk	Enrolment of participants and allocation performed by blinded physician.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo controlled
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow‐up
Selective reporting (reporting bias)	Low risk	No selective reporting
Other bias	Unclear risk	None found.

mRS: modified Rankin Scale